News

Protalix BioTherapeutics Highlights PRX-115 Phase I Results

Protalix BioTherapeutics Highlights PRX-115 Phase I Results

Protalix BioTherapeutics Showcases Impressive PRX-115 Findings

Protalix BioTherapeutics, Inc. (NYSE American: PLX), is making headway in the biopharmaceutical landscape with the presentation of its Phase I clinical trial data for PRX-115. This product candidate is an innovative PEGylated uricase aimed at treating uncontrolled gout. The company will share these valuable insights in a late-breaking poster at the upcoming American College of Rheumatology Convergence 2024.

Key Details on PRX-115 Presentation

The presentation, titled 'Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels', will occur during a significant session dedicated to late-breaking posters. This event is scheduled for November 18, at 10:30 AM to 12:30 PM Eastern Standard Time.

Who Will Present?

Orit Cohen Barak, Ph.D., from Protalix Ltd., will present the findings. Researchers look forward to insights drawn from the clinical trial outcomes.

Protalix's Innovative Approach

Protalix BioTherapeutics has distinguished itself through its proprietary ProCellEx plant cell-based protein expression system, allowing for the production of therapeutic proteins. This method is pivotal in the development of PRX-115 and represents a novel approach in biopharmaceutical manufacturing.

Milestones in Biopharmaceutical Development

In a landmark move, Protalix became the first company to gain FDA approval for a protein produced via its plant cell-based expression system. This pioneering achievement not only showcases the capability of the ProCellEx technology but also sets a precedent for future therapeutic developments.

Products in the Pipeline

Alongside PRX-115, Protalix is advancing several candidates targeting prevalent medical issues. This includes PRX–119, which is focused on NETs-related diseases, demonstrating the company’s commitment to addressing substantial gaps in treatment options.

Collaborative Efforts and Future Endeavors

Protalix continues to strengthen its market position through strategic partnerships. Its collaboration with Chiesi Farmaceutici S.p.A. is aimed at the global advancement and commercialization of Elfabrio, which secured approval from the FDA and the European Medicines Agency.

Contact Information

Investors seeking more details on Protalix's developments can reach out to Mike Moyer, Managing Director at LifeSci Advisors, at +1-617-308-4306 or via email.

Frequently Asked Questions

What is PRX-115?

PRX-115 is a recombinant PEGylated uricase being developed for the treatment of uncontrolled gout.

When is the presentation about PRX-115?

The presentation will take place on November 18, during the ACR Convergence 2024 event.

Who is presenting the PRX-115 data?

Orit Cohen Barak, Ph.D. from Protalix Ltd., will be the presenting author.

What are the key benefits of the ProCellEx technology?

This technology allows for the efficient production of recombinant therapeutic proteins, offering a novel method of manufacturing at industrial scale.

What other products is Protalix developing?

In addition to PRX-115, Protalix is developing PRX–119 and other candidates aimed at various therapeutic markets.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Composites One Unveils Game-Changing eCommerce Platform

Updated Category News Views 21

A New Era for Composites One? You know how companies often blast updates nobody asked for? Well, Composites One finally flipped the script. They've rolled out a completely revamped eCommerce platform across North America, and here's the kicker—it's actually built from the ground up on customer feedback. Yeah, they took the time to ask manufacturers what they needed for...

Continue Reading
Orthocell's Remplir™ Hits Record U.S. Sales in October

Updated Category News Views 176

Orthocell's October Surprise with Remplir™ Sales Well, isn't this a breath of fresh air? Orthocell Limited just reported a staggering rise in its U.S. Remplir™ sales for October 2026. We're talking 92 units shifting off the shelves, pulling in a tidy AU$279,000. That's an 84% leap compared to the average monthly sales of 50 units in Q1 FY27. It seems the company's...

Continue Reading
Amazon and CarbiCrete Innovate with Cement-Free Pavers

Updated Category News Views 88

Amazon Makes a Play for the Planet Look, I'm not one to sprinkle sugar on a cement-related chat, but I gotta say, this CarbiCrete deal has got my attention. Amazon, a titan known for its logistical empire, is diving headfirst into cement-free territory with CarbiCrete's products. In a world where cement production has been a stubborn carbon belcher, there's something big...

Continue Reading
D-Wave Quantum Faces Legal Heat: Key Investor Timelines

Updated Category News Views 76

Trouble Surfacing for D-Wave Quantum Investors It's another day, another dollar slipping out of an investor's pocket. Welcome to the circus. Today's main act? D-Wave Quantum, Inc., sporting a 9.51% drop in stock value. Now, those holding NASDAQ: QBTS shares during that class period between late February and August of 2026 might want to listen up. The lawyers over at...

Continue Reading
Investigation Looms Over ADT, Instacart, Ultralife Deals

Updated Category News Views 68

Corporate Deals Under the Microscope: What's at Stake? The headlines are shouting: ADT, Instacart, and Ultralife are all embroiled in merger activities that might not exactly be what shareholders signed up for. On the surface, you've got big names like DoorDash stepping up to snag some of these firms, but the question here is whether the deals are truly fair—or if...

Continue Reading
Milwaukee Cylinder Unveils Tech for Longevity in Tough Conditions

Updated Category News Views 115

Innovation Meets Contamination: ABC™ Technology Unleashed In the gritty halls of industrial manufacturing, equipment uptime can be the thin red line between profit and chaos. Milwaukee Cylinder just kicked it up a notch with their latest concoction: Active Barrier Chamber (ABC™) technology. This gizmo isn't just another shiny trinket; it's a genuine attempt to wrestle...

Continue Reading
Infinix Unveils Global Flagship Store in Bali

Updated Category News Views 140

Innovating Retail: Infinix Takes a Bold Step Imagine stomping the well-trodden grounds of Bali and striking the jackpot of tech experiences. That's right, Infinix is making waves with its first global Flagship Concept Store. Unveiled on October 31st, this venture is a serious flex from the tech giant, and it's absolutely in no mood to play small. The Flagship Store: A Hub...

Continue Reading
Abracon Unveils Engineer-Focused Website Features

Updated Category News Views 59

Pushing the Needle in Digital Engagement Some days, the market talk brews hotter than a Texas barbecue, and today it’s Abracon serving up something new. They're tossing engineers a fresh digital bone with revamped website accounts. No bells or whistles, just a clean shot at making techies' lives easier as they tinker and design. It's a world where getting your hands on...

Continue Reading
Fresenius, WuXi Biologics Blaze New Biosimilars Trail

Updated Category News Views 148

Fresenius Bets Big on Biopharma with WuXi Partnership A deal inked by Fresenius and WuXi Biologics is stirring up the biosimilars pot, aiming to widen Fresenius' grip on the market tenfold. We're not talking small potatoes here; we're talking up to 66 biosimilar molecules against a hefty backdrop of more than €370 billion in originator sales. It's as if they've said,...

Continue Reading
Tampa Welcomes Global Art Fair October 2026

Updated Category News Views 73

Tampa Steps into the Global Art Scene Get this, Tampa is gearing up for its slice of the global art pie. Come October 2026, the Tampa Convention Center will transform into a bustling hub of creativity and culture. With over 300 artists slated to pour in from every corner of the globe, this isn't just any old art fair—it's Art Fair Tampa, and it's promising to be a...

Continue Reading

Top 5 Most Recently Viewed Articles

Investment Boost: Collective Mining's Strategic Agreement

Updated Category News Views 123

Agnico Eagle's Strategic Investment in Collective Mining Collective Mining Ltd. (NYSE: CNL) is excited to announce a significant investment from Agnico Eagle Mines Limited. This partnership marks a substantial step forward for the company, reflecting confidence in its growth strategy and ongoing projects. Details of the Investment Under the terms of the agreement, Agnico...

Continue Reading
Transforming $100 into Significant Gains with Nike's Growth

Updated Category News Views 38

Transforming $100 into Significant Gains with Nike's Growth Nike (NYSE: NKE) has consistently delivered impressive performance in the stock market over the past two decades. With an annualized return of 11.56%, it has outperformed many other investments, showcasing its strong market presence and growth potential. As of now, Nike boasts a market capitalization of an...

Continue Reading
Earnings Reports Fuel High Hopes for Levi Strauss and Markets

Updated Category News Views 159

Financial Landscape Heading Into Earnings Season With the market entering a pivotal moment, the atmosphere is charged with excitement as pivotal earnings reports loom on the horizon. The S&P 500 and Nasdaq Composite kicked off the week at record highs, marking significant achievements for those indices. The Dow Jones Industrial Average, after gaining 2.3% last week,...

Continue Reading
Ongoing Investigation into Flywire Corporation: What Investors Need to Know

Updated Category News Views 120

Understanding the Investigation of Flywire Corporation The ongoing investigation into Flywire Corporation continues to capture the attention of investors. This matter arises from concerns regarding potential violations of federal securities laws associated with the company. For individuals who have invested in Flywire and are worried about possible losses, it is crucial...

Continue Reading
Fox Corp Analyst Downgrade Sparks Concerns Over Growth

Updated Category News Views 329

Understanding Fox Corp's Recent Analyst Downgrade David Joyce, an analyst from Seaport Research, has recently revised his rating on Fox Corp (NASDAQ: FOX, FOXA) from Buy to Neutral. This decision is largely driven by the typical seasonal patterns observed in September, as the market begins to respond to the evolving political landscape. The Role of Political Advertising...

Continue Reading